Breastfeeding after breast cancer is feasible and safe
New data show that it does not increase the risk of breast cancer recurrence or development of secondary breast cancer in women, nor does it carry any health risks for the child
KRAS and TP53 may have a key role in the development of pancreatic cancer
Studies provide new insights into the driver landscape of these gastrointestinal tumours and show improved prediction of patient-specific outcomes.
Leveraging team science to exploit the tumour’s ‘Achilles heel’ with PARP inhibition: a journey of discovery and perseverance
Extensive research identified the deficiency of a highly accurate DNA repair process known as homologous recombination as an ‘Achilles heel’ in cancer, and led to the development of PARP inhibitors as single-agent therapies
Liquid biopsy plays a growing role in early-stage lung cancer
Research is moving forward to understand the value of this blood-based technology as a prognostic tool
New data add to current knowledge on how to optimise treatment in EGFR-mutant NSCLC
The use of targeted agents in first and subsequent lines of therapy is improving outcomes in patients with mutated lung cancer progressing on standard chemotherapy, but a biomarker- or precision-guided approach is needed
Study findings confirm the benefits of BRAF and MEK inhibitors in mutated non-small cell lung cancer
Longer duration of efficacy reported for encorafenib plus binimetinib as a treatment for NSCLC harbouring a BRAF V600 mutation
Novel ALK-selective TKIs show early efficacy in advanced NSCLC with rare mutations
Further studies are needed to understand the position of the fourth-generation agents NVL-520 and NVL-655 in the treatment paradigm of mutated lung cancer
Long-term survival benefits reported with neoadjuvant immunotherapy combinations in stage III melanoma
Neoadjuvant immunotherapy combinations were associated with high long-term survival rates and were superior to adjuvant nivolumab in patients with resectable melanoma, according to a phase III study and analysis of pooled studies
Taxane- and anthracycline-sparing regimens show promise in high-risk, early-stage breast cancer
High rates of pathological complete response were reported with neoadjuvant datopotamab deruxtecan plus durvalumab in patients with specific subtypes of breast cancer and at high risk of recurrence
Neoadjuvant chemoradiotherapy has no role in the treatment of operable gastric cancer
Final late-phase trial results show that the addition of pre-operative chemoradiotherapy to peri-operative chemotherapy does not improve long-term outcomes in patients